Phase III clinical study of DQ-2466 -Double-blind controlled study of fixed-dose and up-titration DQ-2466 regimens in subjects with persistent or permanent atrial fibrillation -

Trial Profile

Phase III clinical study of DQ-2466 -Double-blind controlled study of fixed-dose and up-titration DQ-2466 regimens in subjects with persistent or permanent atrial fibrillation -

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Carvedilol (Primary)
  • Indications Atrial fibrillation
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Daiichi Sankyo Company
  • Most Recent Events

    • 07 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top